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Abstract Metastatic disease is the major cause of death in
breast cancer patients. Patients presenting with metastases
cannot be cured, and as a consequence, treatment is
palliative and focuses on prolonging survival and main-
taining quality of life. Numerous mouse models have been
generated in which human breast cancer development and
metastasis have been studied, ranging from spontaneous
and carcinogen-induced models to transplantation models
and genetically engineered mouse models. Here, we
summarize past progress and highlight present develop-
ments in modeling breast cancer invasion and metastasis in
genetically modified mice, and the impact it may have on
the development of innovative anticancer therapies.
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Introduction
Breast cancer is the most common malignancy among
females in the Western world, resulting in approximately
half a million deaths annually mainly due to metastatic
disease [1]. While primary breast tumors can be treated
with increasing success, many tumors are not eradicated by
local treatment and systemic adjuvant therapy, and will
relapse, often leading to the incurable phase of cancer,
metastatic disease. Although frequently regarded as such,
tumors are not a homogeneous population of immortalized
cells. Recent data have shown that a primary tumor consists
of several populations of malignant cells, each of which
may respond differently to conventional treatment [2, 3].
Specifically, certain tumor cells that present ‘stem cell like’
characteristics were shown to be causal to radiotherapy
resistance [4–6]. In analogy to this, approximately 40% of
breast cancer patients show resistance to standard chemo-
therapy, resulting in tumors that will relapse and subse-
quently metastasize.
Metastatic disease is a complex phenomenon, in which
cells have to detach from their microenvironment, counter-
act the resulting pro-apoptotic signals, invade surrounding
stroma, enter the vasculature and colonize distant sites.
These processes depend on the activation and inhibition of
multiple signal transduction pathways and their targets,
which are currently ill defined. Research on breast cancer
metastasis has greatly profited from recent advances in
modeling metastatic disease in mice, using both trans-
plantation techniques and genetic modification [7, 8]. Due
to the complex nature of the metastatic process, models that
mimic the entire disease are scarce, but nevertheless
emerging. This review will focus on past and present
mouse models in which breast cancer invasion and
metastasis are studied. We will discuss the lessons learned
from these models and the usefulness of the resulting data
in the identification of targets for drug development.
Human Breast Cancer
Breast cancer is a genetic disease and, consequently, its
incidence increases with age. Among the numerous risk
factors (e.g. late menopause, nulliparity, long term post
menopausal hormonal replacement therapy, obesity and
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alcohol) the most predictive risk factor is a family history of
breast cancer [9]. Approximately 5–10% of all breast
cancers result from certain forms of hereditary cancer
predisposition, such as Li-Fraumeni syndrome [10, 11],
Cowden’s disease [12], and BRCA mutation carriers [13].
All breast cancers, however, have acquired somatic genetic
abnormalities, resulting in mutated or overexpressed cancer
genes (e.g. TP53, MYC, BCL2, CCND1) [14]. Large-scale
sequencing of breast cancer genomes is currently being
performed by several groups [15, 16], but the exact number
and type of mutations that are required for breast cancer
initiation and metastasis in humans is still unknown.
Breast Cancer Progression and Metastasis
Breast cancer is a clinically heterogeneous disease. Aggres-
sive breast cancers not only show multiple morphological
phenotypes, the rate and onset at which metastasis occurs
also varies considerably. For example, aggressive disease
with distant metastases within 3 years, as well as
manifestation of distant metastases more than 10 years
after initial diagnosis are not uncommon [17]. Sites of
metastasis may differ per subtype, but mainly comprise
lung, pleura, liver and bone [18] (Fig. 1). Human pathology
has defined a plethora of histological subtypes, based
mainly on morphological criteria, of which ductal and
lobular carcinomas represent the majority (Table 1).
Although informative, the ductal and lobular classification
is a poor prognostic indicator of metastatic risk [19] and
can be misleading, as it implies cellular origin. To better
define the basis of breast cancer heterogeneity, gene
expression profiling has recently been used to identify
molecular subtypes of breast cancer with distinct clinical
features [20, 21]. Similarly, supervised classification of
gene expression profiling data has yielded prognostic gene
expression signatures that predict risk of breast cancer
metastasis [22, 23]. Yet other groups have identified gene
expression signatures that predict the site of metastasis
[24, 25]. Tumor or metastasis-specific expression profiles
can thus help to point to distinct signaling pathways that
contribute to metastasis. In this way, “tailored” intervention
strategies may be developed to improve the currently
relatively poor clinical management in both the adjuvant
and metastatic setting [9–14]. Conventional prognostic
markers that predict or correlate with breast cancer
metastasis are not very reliable and are mainly based on
phenotypic criteria, such as tumor size, histological grade,
lymph node status and (lymph)angioinvasion [26–29].
More recently, clinicians have also employed the aberrant
expression of proteins (uPA/PAI1, steroid receptors,
ERBB2) to predict disease outcome [28–32], or as targets
for intervention strategies [33, 34].
Breast Cancer Diagnosis and Treatment
Systemic screening by means of mammography may result
in early diagnosis, depending on tumor subtype. These
clinical examinations have resulted in a 25–30% decrease
in mortality from breast cancer, mainly in postmenopausal
women [35]. Among women with breast cancer who
present tumors less then 2 cm in diameter, or up to 5 cm
without signs of axillary node metastasis, the 20 year
recurrence-free survival is approximately 77 and 64%,
respectively [27, 36]. Given the fact that predictions
regarding recurrence and metastasis are difficult to make,
systemic adjuvant therapy following local treatment is now
widely applied to help eradicate tumor cells that might have
already spread systemically [9, 37]. Currently, depending
on the guidelines used, 50 to over 80% of breast cancer
patients receive adjuvant therapy, even though only 25–
40% of them will relapse and ultimately die of metastatic
disease [38]. Hence, many women are ‘over-treated’ and
will suffer unnecessarily from the harmful side effects of
standard chemotherapy. Adjuvant chemotherapy regimens



















Figure 1 Dissemination sites of breast cancer metastasis at autopsy.
Percentages obtained from 2,050 cases are shown. Adapted from [18].
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often consist of repetitive administrations of combinations of
drugs [39]. Frequently used combinations are CMF (cyclo-
phosphamide, methotrexate, fluorouracil), FAC (fluoroura-
cil, doxorubicin, cyclophosphamide), FEC (fluorouracil,
epirubicin, cyclophosphamide) and AC (doxorubicin, cy-
clophosphamide), sometimes followed by a taxane [9].
These therapies are followed by endocrine therapy in case
of hormone receptor-positive disease, and combined with
the anticancer drug trastuzumab in case of ERBB2 gene
amplification [40]. Other targeted therapies against VEGF
and EGFR are now in advanced stages of clinical testing. In
addition to these therapies, scores of other small molecule
inhibitors and biologicals that antagonize the activity of
specific enzymes or protein–protein interactions are currently
under development [33].
Mouse Models of Human Breast Cancer
Mouse models have made an important contribution to our
understanding of breast cancer progression and metastasis.
Novel, ‘humanized’ mouse models are at present being de-
veloped and will be pivotal to pinpoint the cardinal events
that govern intrinsic cues of tumor cells and micro-
environmental interactions that propel metastatic disease.
Also, they will be important tools to test and validate novel
treatment strategies.
Mice are Not Little Humans
The laboratory mouse has been used extensively in cancer
research for a number of reasons. First, the mouse is a
mammalian organism that shares many anatomic, physio-
logical and genetic similarities with humans. Second, the
mouse germ line can be easily manipulated whereby genes
may be overexpressed or inactivated, even in a time or tissue-
specific manner. These characteristics render mice very
attractive as a study object for human cancer pathogenesis.
But how alike are mice and men? Does a mouse mammary
tumor truthfully reflect human breast cancer?
Mice are about 3,000 times smaller, live on average 40
times shorter and undergo approximately 100,000 fewer
cell divisions in their lifetime than humans. Yet, they are as
susceptible to developing cancer as humans [41]. Despite
the fact that mice should experience far less genetic damage
during their relatively short life span, both mice and men
show a cumulative cancer incidence of approximately 30%.
Thus, humans must have evolved intrinsic anti-tumor
mechanisms which have allowed them to decrease cancer
susceptibility [42]. Mice mainly tend to develop tumors of
mesenchymal origin, whereas human age-related cancers
are mostly derived from epithelial progenitor cells [43].
Apart from the obvious environmental factors, such as
alcohol, diet and tobacco, there are clear biological differences
between mice an men that are likely to contribute to
differences in cancer risk and spectrum. One major difference
comprises telomere erosion during malignant transformation
of human cells. In contrast to human cells, mouse somatic
cells express biologically active telomerase, an enzyme that
is required for maintenance of chromosome ends [44].
Accordingly, mouse telomeres are 40 to 60 times longer
than human telomeres and, consequently, mouse cells are
more easily immortalized than human cells, which must
undergo a second genetic hit to overcome telomere crisis
[45]. Despite these discrepancies, mouse models have
demonstrated their utility in cancer research and have made
a substantial contribution in understanding human tumor
etiology.
The Mouse Mammary Gland
In order for the stem cells in the neonatal mammary bud to
develop into an adult mammary gland, progenitor cells
need to propel and maintain a delicate and fine-tuned
balance of multiple signaling pathways. These pathways,
which include among others Wnt, Notch, EGF, and TGF
signaling, are triggered to enable cells to invade stroma,
proliferate, acquire anoikis resistance, undergo apoptosis,
differentiate and induce angiogenesis [46, 47]. Also,
stromal elements present in the mammary gland, such as
adipocytes, fibroblasts, endothelial and immune cells, will
intricately interact with mammary epithelium in order to
successfully form a functional mammary gland [48]. These
processes not just are used for mammary gland develop-
ment; during pregnancy, the mammary gland undergoes
similar morphological and environmental changes. An
enormous response is displayed upon release of female
reproductive hormones, including the induction of mam-
mary gland formation, differentiation of cells into milk-
secreting units and subsequent massive involution after
parturition. It is this remarkable flexibility of mammary
Table 1 Histopathological subtypes of invasive breast carcinoma.













Invasive papillary <3 Unknown
Metaplastic <5 Unknown
Adapted from [38].
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epithelial cells that breast cancer cells hijack during their
progression and metastasis.
Transplantation Models of Breast Cancer
Transplantation of cells derived from breast cancer has been
extensively used to study several aspects of breast cancer
pathology in situ. A major factor to be considered,
however, is the site of tumor cell injection. For example,
several aspects of the metastatic process (tumor–stroma
interactions, detachment and local invasion, extravasation)
are omitted when injecting tumor cells into a vein (IV).
Injections into the left ventricle of the heart (intracardiac;
IC) which excludes the direct trapping of tumor cells in the
lungs, facilitate a broader dissemination spectrum and are
thus successfully being using to study bone metastasis [49].
Orthotopic transplantations, and to a lesser extent ectopic
transplantations, mimic additional aspects of metastasis,
because cells have to form a primary tumor as well as
actively trigger local invasion and extravasation, which are
key aspects of metastasis.
Allograft Models
Transplantation of tumor cells into syngeneic recipient mice
with identical genetic backgrounds (allografting) prevents
graft versus host reactions, which is a problem when
studying human cancer cells in mice (xenografting). Most
allograft models do not show extensive metastatic behavior,
especially to bone. Nevertheless, specific selection in vivo
has resulted in cancer cell lines (e.g. 4T1.2 cells derived
from a spontaneous BALB/C mammary tumor) that show
enhanced metastatic potential to lungs, liver, bone and brain
when injected intracardiacally or at orthotopic sites [50,
51]. Gene expression profiling of several 4T1.2 sublines
with different metastatic potential has led to the identifica-
tion of Twist as a key factor in breast cancer metastasis
[52]. Twist may contribute to metastasis by promoting an
epithelial to mesenchymal transition (EMT) characterized
by loss of E-cadherin-mediated cell–cell adhesion, activa-
tion of mesenchymal markers, and induction of cell
motility.
Xenograft Models
Metastasis can be also studied by transplantation of human
tumor cells in mice, a technique that is restricted to
immune-compromised or immune deficient animals be-
cause of the inevitable host versus graft reactions [53, 54].
As a consequence, the contribution of an intact immune
system—which plays a key role in the metastatic process—
cannot be studied in these xenograft models. Also, stromal
components that can foster carcinoma-associated fibroblasts
have been shown to activate and maintain SDF1-mediated
signaling and subsequent induction of angiogenesis [55, 56].
Despite these limitations, several studies have successfully
utilized a human cell line, MDA-MB-231, in the search for
factors that regulate metastasis. This cell line is derived
from pleural effusion fluids of a breast cancer patient, and
displays colonization of multiple target organs, such as
liver, lung, brain, adrenal glands and bone upon orthotopic
and subcutaneous transplantation [57, 58]. Massagué and
colleagues have successfully used in vivo selection of
MDA-MB-231 cells in nude mice to identify and validate
genes that control metastasis to bone and lung [24, 25].
Bone metastatic subpopulations of MDA-MB-231 cells
were selected by several rounds of intracardiac injections
and isolation of metastatic nodules in the bones of the
injected mice [25]. Lung metastatic variant sublines of
MDA-MB-231 were selected by repeated tail vein injec-
tions and isolation of lung lesions [24]. Subsequent gene
expression profiling of parental MDA-MB-231 cells and
metastatic variants yielded sets of genes that promote
metastasis to bone or lung. Bone metastasis of MDA-MB-
231 cells appears to be mediated by a limited number of
genes, including the angiogenesis factors FGF5 and CTGF,
the activator of osteoclast differentiation IL11, the bone
matrix-degrading metalloproteinase MMP1 and the bone-
homing chemokine receptor CXCR4 [25]. CXCR4, which
is highly expressed in human breast cancer cells, is an
important determinant for organ-specific metastasis because
CXCR4-positive tumor cells are actively recruited by
SDF1-expressing metastatic target organs [59]. Gene
expression profiling of lung metastatic MDA-MB-231
variants yielded a set of 54 genes including—besides
CXCL1, MMP1 and MMP2—the EGF family member
EREG, the cell adhesion molecule SPARC, the cell adhesion
receptor VCAM1, the interleukin receptor IL13RA2, the
inhibitor of cell differentiation ID1 and the cyclooxygenase
COX2 [24]. Functional validation of these genes showed
that some (e.g. ID1) serve dual functions in both the
primary tumor and in the lung microenvironment, whereas
others (e.g. IL13RA2, SPARC and VCAM1) contribute only
to lung metastasis formation.
Xenografting in Humanized Mice
Obviously, caution should be taken when transplanting
human tumor cells into mice, as human cells are not fully
adapted to the mouse microenvironment. Indeed, attempts
to recapitulate human breast epithelial morphogenesis by
introducing human MECs into cleared mammary fat pads
of mice have been unsuccessful. To circumvent this
limitation, Kuperwasser and coworkers have developed an
orthotopic xenograft model in which both the stromal and
epithelial components of the reconstituted mammary gland
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are of human origin [60]. To this end, mouse mammary fat
pads were “humanized” by introducing human breast fibro-
blasts into cleared mouse glands, and at a later time point
engrafting human breast epithelial and stromal cells into the
humanized fat pads. This system allows for full develop-
mental and functional outgrowth of human breast ducts and
lobules and permits orthotopic grafting of primary human
breast cancer tissue and cells. Another strategy to produce
humanized mouse xenograft models of breast cancer
metastasis involves injection of human breast cancer cells
into immunodeficient NOD/SCIDmice carrying human bone
grafts [61]. Of 13 breast cancer cell lines tested, only
SUM1315 cells formed lung and bone metastases. Impor-
tantly, bone metastasis was to the human implant and not to
the mouse skeleton, suggesting species-specific homing
characteristics.
Conventional Transgenic Mouse Models of Breast Cancer
Historically, mammary gland-specific overexpression of
oncogenes has been the primary means to study breast cancer
in transgenic mice. The initial oncogenes to be discovered
were genes found overexpressed through genomic amplifi-
cation in human breast cancers, or genes identified as targets
of mouse mammary tumor virus (MMTV) insertional
mutagenesis experiments [62, 63]. Consequently, the
MMTV long terminal repeat (MMTV-LTR), which contains
the retroviral promoter and enhancer elements, has been
widely employed to drive mammary gland-specific over-
expression of a gene of interest in transgenic mice [64].
Also, other promoters, mainly derived from genes encoding
mammary gland-specific (lactogenic) proteins, have been
used to create a multiplicity of transgenic mouse models of
breast cancer. An overview of promoters used for mammary
gland-specific transgenesis is shown in Table 2. A negative
aspect of many of these models is that tumors have to be
induced by hormonal stimuli, triggering not only transgene
expression but also developmental cues, which may affect
tumor etiology. Conversely, female reproductive stimuli are
also present systemically in the absence of pregnancy or
lactation and can therefore induce undesired expression of
transgenes, a known phenomenon when using, for example,
whey acidic protein (WAP) promoter elements. Also,
lymphatic dissemination and subsequent metastasis, espe-
cially to bone, are rare in conventional transgenic mouse
models, which is most likely due to the rapid onset and
progression of the primary neoplasm [8] (Table 3). In an
ideal world, the promoters used in mouse models should not
only be mammary-specific, but also hormone-independent.
This requirement induces an intrinsic paradox that has
prevented the development of the ultimate model using the
aforementioned tools.
Table 2 Promoters used for mammary gland-specific expression.
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Conventional Transgenics: Polyoma Virus Middle
T Antigen
The Polyoma middle T-antigen (PyMT) has the ability to
convert established cell lines to an oncogenic state. Middle
T antigen is a membrane bound polypeptide that can be
regarded as a constitutively active analogue of a receptor
that harbors docking sites for a number of effector proteins
used by tyrosine kinase receptors to stimulate mitogenesis
[65]. Mammary gland-specific overexpression of PyMT
using the MMTV promoter results in multifocal adenocar-
cinomas with a short median latency and the formation of
metastasis to lungs and lymph nodes [66]. This mouse
model has since been used extensively because it shares
many characteristics with human breast tumors. First,
tumors develop with high penetrance and show gradual
loss of estrogen and progesterone receptors. Second, the
multistage progression from hyperplasia to a full-blown






Site of metastasis Reference
1 2 3
C3(1) SV40 LT 180 Lung [126]
H19 Igf2 >280 Lung, liver, spleen [125]
MT Met (Y1248H and M1268T)a 300 Lung, LN, kidney, heart [88]
MMTV Cox-2 210 LN [127]
MMTV Wnt-1 240 Lung, LN [118]
MMTV Wnt1 Fgf-3 120 Lung, LN [128]
MMTV Ron 200 Lung, liver [92]
MMTV ΔN β-catenin Trp53Δ/+ 300 Lung [128]
MMTV Chk2D347A 290 Lung, Spleen [129]
MMTV ErbB2 200 Lung [77]
MMTV ErbB2 TGFβ 200 More lung metastases [80]
MMTV ErbB2 TGFβ (SR2F) 240 Less lung metastases [82]
MMTV ErbB2 S1004A 330 More lung metastases [130]
MMTV ErbB2 activated 120 Lung [76]
MMTV ErbB2 (YB and YD) ∼150 Lung [78]
MMTV ErbB2 (YB) TGFβR1 (AAD) 270 Lung [131]
ErbB2 (YB) TGFβR2 (Δcyt) Less extravascular
ErbB2 (YD) TGFβR1 (AAD) More extravascular
MMTV ErbB2 (YD) ItgB41355T 150 Inhibition of metastasis [132]





55 More lung metastases [81]
MMTV PyMT VEGF 40 Lung [72]
MMTV PyMT Irs1Δ/Δ 80 More lung metastases [70]
MMTV PyMT uPAΔ/Δ 50 More lung metastases [69]
MMTV PyMT CD44Δ/Δ 105 More lung metastases [68]
MMTV PyMT PlgΔ/Δ 50 Less lung metastases [71]
MMTV PyMT MEKK1Δ/Δ 90 Lung, delayed [133]
MMTV PyMT TGFβR2MGΔ 60 More lung metastases [83]
WAP HGF 50 Lung [89]
WAP RAS 180 Lung [134]
WAP SV40 LT 300 Lung, LN [135]
WAP Notch-4 200 Lung [136]
MMTV-rtTA ErbB2 activated Lung (reversible) [107]
MMTV and
WAP-rtTAb
Cre Trp53F5-6 280/330 Lung, liver [102]
K14 Cre Trp53F2-10 Cdh1F4-15 200 Lung, LN, liver, GI tract,
peritoneum, pancreas
[103]
a Only one animal was tested for each mutation.
b Tet–responsiveness was not functional in this promoter.
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malignancy is represented in MMTV-PyMT mice. Finally,
metastatic potential appears to be independent of hormonal
fluctuations with a reproducible progression rate [67].
Several labs have employed the MMTV-PyMT model to
define and substantiate a role for genes that have been
implicated in tumor progression and metastasis, such as
CD44 [68], uPA (69), Irs1[70] and Plg [71] (Table 3). Also,
overexpression of the blood vessel angiogenic factor
VEGF-A in MMTV-PyMT mice resulted in accelerated
formation of lung metastasis, not only by promoting tumor
angiogenesis but also by sustaining tumor proliferation and
survival [72].
Conventional Transgenics: Receptor Tyrosine Kinases
The receptor tyrosine kinase (RTK) ErbB2 (aka Her2 or
Neu) has a long track record of clinical interest because of
its overexpression in many breast tumors. Hence it is being
used as a strong prognostic indicator, predictor of metastasis
and a target for treatment [73]. ERBB2 is amplified in ap-
proximately 15 to 30% of all breast cancers [30], especially
tumors from patients with lymph node metastases [74].
ErbB2 is an EGF family-type RTK, which normally
regulates mammary growth and differentiation. Tissue
culture experiments have shown that overexpression leads
to transformation and invasion in the absence of ligand
[75]. Transgenic mice that have been engineered to express
wild type and mutant forms of ErbB2 under the control of
MMTV promoter, show formation of multifocal adenocar-
cinomas that metastasize to lung [76–78].
Like the MMTV-PyMT model, the MMTV-ErbB2
mouse has formed the basis for many experiments to
investigate cooperating events in breast cancer. A potent
inducer of invasiveness is TGFβ, a secreted cytokine that
exerts its activity by binding to distinct serine/threonine
kinase receptors. Interaction of TGFβ with its receptor can
have a dual outcome; it can suppress initial tumorigenesis,
but conversely, can also stimulate invasion and metastasis,
which is accompanied by an epithelial to mesenchymal
transition (EMT) and proangiogenic and immune suppressive
effects on the tumor microenvironment [79]. Furthermore, it
has been shown to play a role as an important mediator of
bone metastasis by increasing the expression of tissue-
specific cytokines [25]. Expression of TGFβ in MMTV-
ErbB2 mice caused more circulating tumor cells and lung
metastases than ErbB2 mice alone. Furthermore, MMTV-
ErbB2;MMTV-TGFβ1 tumors contained higher levels of
active Smad2, Rac1, Pkb/Akt, MAPK and p38 [80].
Interestingly, primary tumor burden was unaltered regard-
less of TGFβ1 signaling. Inducible expression of TGFβ in
the MMTV-PyMT mouse model of metastatic breast cancer
also corroborated these findings [81]. In vivo inhibition by
expressing either TGFβ antagonist SR2F, TGFβ receptor
type I (TGFβR1), or dominant negative TGFβRII, reduced
the number of lung metastases, thus substantiating the pro-
metastatic functions of TGFβ1 signaling in MMTV-ErbB2
mice [82]. Somewhat intriguing is the finding that condi-
tional ablation of TGFβRII in the MMTV-PyMT mouse
resulted in an increased number of metastatic lung foci [83].
Hyperactivation of hepatocyte growth factor (HGF) and
its receptor MET can cause transformation of cells, leading
to the initiation or progression of malignancy. Under these
conditions, MET can disturb the subtle balance between
growth and apoptosis, and induce unrestricted growth and
motility, accounting for cellular transformation, invasion
and metastasis [84]. Although activating mutations or
genomic amplification have not been reported in human
breast cancer, Met amplification is frequently observed in
BRCA1- and p53-deficient mouse tumors [85]. Moreover,
overexpression of MET has been found to predict metas-
tasis and survival in early-stage breast cancer [86]. Zinc-
inducible overexpression of HGF in MT-HGF mice resulted
in diverse tumorigenesis, including mammary gland
tumors, without apparent metastasis [87]. Overexpression
of a mutant form of the Met receptor, but not the wild type
protein, resulted in mammary tumors which metastasized to
lung, lymph node (LN), kidney and heart [88], suggesting
ligand-independent functions of mutant Met. Recently,
HGF was overexpressed in the mammary gland using a
WAP promoter, resulting in mammary tumors with a
median latency of 210 days, which metastasize to the lungs
[89]. The RON receptor is a family member of the Met
proto-oncogene, and recently, RON has been found to be
overexpressed and constitutively activated in approximately
50% of primary breast cancer cases [90]. In addition,
increased expression of the RON receptor strongly corre-
lates with the more aggressive phenotype observed in node-
negative breast tumors [91]. Transgenic overexpression of
Ron in MMTV-Ron mice is sufficient to induce mammary
tumors that metastasize to the liver and lungs with high
penetrance. In contrast to the MET RTK, activating
mutations in Ron did not confer a higher tumor incidence
or metastasis rate [92].
Conditional Mouse Models of Breast Cancer
Human tumors are caused by accumulating genetic mutations
in a distinct subset of cells that have a given susceptibility for
the molecular consequences of such a mutation. In sporadic
cancer, these mutations will affect a single cell that is
embedded in a normal microenvironment. Conventional
mouse models of human breast cancer have largely been
based on the activation of a single dominant gene in a pan-
organ setting. As a consequence, a large cellular compartment
is targeted for oncogenesis, a situation not reflective of the
human condition. In human cancer, mutations occur sporad-
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ically in a stochastic manner and accumulate over time,
leading to tumors with a distinct gene expression signature
that determines metastatic behavior and clinical outcome
[22]. Furthermore, most mouse mammary tumors arising in
conventional transgenic models do not recapitulate the
morphology of common human breast cancers [93]. Finally,
tumor metastasis in conventional breast cancer models is
largely restricted to lung, whereas most human tumors
initially show lymphatic spread.
These limitations of conventional models have urged
scientists to develop more advanced mouse models based on
inducible systems that permit somatic and stochastic
mutation of target genes in a wild type background [94].
Successful conditional gene (in)activation can be achieved by
using site-specific recombination systems, such as the Cre/
loxP from bacteriophage P1 or the FLP/FRT system from S.
cerevisiae. To obtain a conditional mutation, coding regions
of a gene are flanked by loxP or FRT elements, which are
inserted in intronic sequences, resulting in functional alleles
and phenotypically wild type animals. Mice carrying
conditional mutations are then crossed to mice expressing
the Cre or FLP recombinase enzyme in the mammary gland,
and as a consequence, only those cells that have expressed
the appropriate recombinase will undergo site-specific
recombination resulting in deletion of the genomic se-
quences flanked by loxP or FRT elements [95] (See http://
www.mshri.on.ca/nagy/floxed.html posted by the Nagy lab
for a database containing all published floxed genes). Future
models may involve ‘double-layered’ systems in which
tissue-specific, reversible gene mutations can be induced in
selected (Cre-expressing) cells at any given time through the
application of inducible (e.g. tetracycline-responsive) ele-
ments incorporated in mammary-specific promoters [96, 97].
Compound mutant mice can thus be bred to investigate the
contribution of multiple mutant alleles, in space and time,
to breast tumorigenesis and metastasis, providing an un-
surpassed degree of flexibility in mouse modeling.
Another interesting system, which may facilitate in vivo
testing of candidate metastasis genes, is based on avian
leukosis virus RCAS (replication-competent avian sarcoma-
leukosis virus LTR splice acceptor)-mediated somatic gene
transfer [98]. This system employs retroviral gene delivery
whereby expression can be targeted to cells of mice
transgenic for the avian subgroup A receptor gene (tva).
This system has recently been employed successfully to
introduce PyMT and ErbB2 in mammary epithelial cells of
MMTV-tva transgenic mice [99]. Moreover, oncogene
collaboration could be assessed by infection of MMTV-
tva; MMTV-Wnt bitransgenic mice with RCAS virus
carrying an activated ErbB2 oncogene. The RCAS-tva sys-
tem may thus be a promising approach to develop flexible
mouse mammary tumor models for rapid evaluation of
candidate metastasis genes.
Conditional Mouse Models of Breast Cancer Metastasis
Conventional mouse models of breast cancer employ activa-
tion or inhibition of genes in a “pan-organ” setting, and, as a
consequence, produce mammary tumors that only poorly
resemble human breast cancer etiology and metastatic
behavior [93]. Hence, new mouse models are needed that
reproduce the salient features of human breast cancer devel-
opment and metastasis. Whereas these conditional mouse
models of breast cancer metastasis are obviously more
complex, the first successful studies show promising results.
Inhibition of p53 function as a consequence of mutation
or genomic loss is found in approximately 50% of human
breast cancer cases [100, 101]. Conditional inactivation of
p53 in the mammary gland using WAP promoter-driven Cre
expression resulted in presumptive Erα-positive tumors that
metastasized to the lungs in 36% of the female mice [102].
However, major discrepancies exist between this model and
human p53-mutated breast cancers, tumor morphology and
metastatic spread. Possible reasons for these differences
may be that (1) conditional mutations are induced in the
wrong mammary gland compartment when using a WAP
promoter, or (2) conditional induction of an additional hit is
required to obtain a ‘humanized’ mouse mammary tumor
with the appropriate metastatic spectrum.
The latter has been explored by studying the consequences
of somatic loss of E-cadherin in a noninvasive mouse
mammary tumor model based on epithelium-specific inacti-
vation of p53. In this setting, stochastic cytokeratin (K)14
cre-mediated inactivation of E-cadherin induces the forma-
tion of mouse invasive lobular carcinoma (mILC), reminis-
cent of the human situation [103]. In contrast to previous
mouse models, metastases in mILC are mostly lymphatic
and spread to lung, liver, gastric tract and peritoneum,
similar to human pathology. Moreover, angiogenesis is
strongly increased in mILC, a phenotype that may be
facilitated by autocrine production of proangiogenic factors.
In summary, the mILC mouse model not only mimics a
human form of breast cancer, but also represents the first
physiologically relevant model to study all aspects of breast
cancer progression and metastasis. The ‘humanized’ pheno-
type in mILC may be to a significant extent credited to a
combination of the tissue-specific promoter used and the
nature of the secondary induced conditional mutation. Given
the tumor incidence and timing, carcinomas are likely to
originate from a mammary gland progenitor cell that ex-
presses CK14 before or during puberty. The main disad-
vantage of using a CK14 promoter to drive cre expression in
mammary epithelium is the fact that this promoter is also
active in other epithelial tissues, including skin. Consequent-
ly, a substantial fraction of the females develop skin tumors,
which arise either prior to or concurrent with the onset of
mILC. To circumvent these problems, we have developed a
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model, based on WAPcre-mediated deletion of E-cadherin
and p53. Here, mammary tumors develop with a similar
latency in a pregnancy-independent fashion and show a
comparable metastatic spectrum and incidence (Derksen
et al., manuscript in preparation).
Regulatable Mouse Models of Breast Cancer Metastasis
It is commonly accepted that tumor formation is a multi-
stage process driven by stepwise acquisition of oncogenic
capacities through (epi)genetic mutations in oncogenes and
tumor suppressor genes [42]. An important question is
whether an oncogene or tumor suppressor that is crucial for
initial tumor development is also required for tumor main-
tenance. Tumors that are “addicted” to a specific genetic
lesion might be effectively treated by genetic or pharma-
cological neutralization of this lesion, e.g. by inhibition of
oncoprotein activity or restoration of tumor suppressor
activity [104]. Using genetically engineered mouse models
with doxycycline- or tamoxifen-inducible gene expression
[95], this question has been successfully addressed for
several oncogenes [105] and tumor suppressors, such as p53
[106]. These mouse models also permit assessment of the
requirement of sustained oncogene overexpression for
maintenance of tumor metastases. This issue has been
elegantly tackled using a conditional mouse mammary tumor
model with doxycycline-inducible, mammary epithelium-
specific expression of activated ErbB2 (MMTV-rtTA;
TetO-ErbB2) [107]. Interestingly, addiction to activated
ErbB2 is maintained during tumor progression and metas-
tasis, since both primary mammary carcinomas and lung
metastases rapidly and fully regress following transgene
deinduction by doxycycline withdrawal. However, ErbB2-
independent tumors recurred in these animals over time.
The Course Ahead
Clearly, mouse models that recapitulate the multiple stages
of breast cancer development and progression have greatly
contributed to our understanding of the molecular mecha-
nisms governing tumor progression and metastasis. Whereas
comparative histopathology is often used to judge a mouse
model on its merits, there is a growing appreciation for the
underlying molecular mechanisms as the key parameters
regulating tumorigenesis and progression. The fact that
tumor progression in some mouse models does not ‘look’
like a human malignancy, does not exclude the possibility
that the affected genes and pathways are similar or over-
lapping. Today, more and more emphasis is being directed
towards molecular profiling techniques to identify deregu-
lated pathways that drive tumor progression and metastasis.
Humanized mouse models are increasingly being used to
extract distinct genetic signatures that correspond to mam-
mary tumors with specific metastatic capacity. This will
allow a thorough comparison of mouse versus human
expression profiles to extract common denominators for a
given tumor phenotype or (organ-specific) metastatic pat-
tern. These efforts are expected to yield candidates which
may lead to the discovery of new diagnostic markers as well
as drug targets for intervention strategies to fight metastatic
disease. The final frontier will nonetheless be the testing of
new strategies for clinical applicability. Although xenografts
have extensively been used as preclinical models, they are
end-stage tumors that do not recapitulate the natural history
of cancer in a histocompatible host and, consequently, have
not excelled in predictive power. Furthermore, they lack
particular interactions with the microenvironment, which
contains key elements that influence tumor development and
metastasis [108–110]. Novel models of in vivo metastasis
are being developed at an expeditious pace and will yield
mice that closely resemble human tumor development and
progression, thus allowing accurate testing of newly
designed agents.
Moreover, tumor development and progression can be
monitored noninvasively for long periods using a growing
array of imaging modalities, such as bioluminescence im-
aging (BLI) [111], fluorescence imaging [112], magnetic
resonance imaging (MRI) [113], positron emission tomog-
raphy (PET) [114], computer tomography (CT) and single
photon emission computed tomography (SPECT) [115].
Finally, intravital imaging using multiphoton or two-photon
microscopy permits real time observation of the dynamics
of tumor growth, extravasation and cell migration, as well as
the contribution of stromal fibroblasts, endothelial cells and
immune cells [116, 117]. We believe the best is yet to come.
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